Drug intelligence / Profile preview

CaLGL-1

Development stage: Unknown
Lead developer: Lanzhou University

Overview

CaLGL-1: sourced facts only. name: "In this study, we found natural product CaLGL-1, which functions as a "quiescent agonist" of TLR2, with its immunostimulatory potential masked by a labile acetal group." [PMID:41764631]; target: "In this study, we found natural product CaLGL-1, which functions as a "quiescent agonist" of TLR2, with its immunostimulatory potential masked by a labile acetal group." [PMID:41764631]; developer: "State Key Laboratory of Natural Product Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, P.R. China." [PMID:41764631]

Targets

TLR2 (Toll-like Receptor 2)

Beyond the preview

Go deeper on CaLGL-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CaLGL-1.